Cabometyx (cabozantinib) costs roughly $100,000 per year of treatment, making it one of the most expensive oral cancer drugs on the market. Medicare Part D data from 2019 shows total spending on the drug exceeded $430 million for just 4,303 patients, averaging about $100,000 per beneficiary per year. Several factors drive that price, from the drug’s unusual mechanism to the economics of cancer drug development.
What Cabometyx Does Differently
Most cancer drugs hit one or two targets. Cabometyx blocks multiple receptor proteins that tumors rely on to grow and spread, including MET, VEGFR2, RET, and AXL. This multi-target approach matters because cancer cells are notoriously good at finding workarounds. When you block a tumor’s blood supply by targeting the VEGF pathway, for example, the tumor often responds by ramping up a protein called MET, which fuels growth through a different route. Cabometyx shuts down both pathways simultaneously, making it harder for the cancer to develop resistance.
Beyond cutting off blood supply and blocking growth signals, the drug also disrupts a signaling chain called PI3K/mTOR that many tumor cells depend on for survival. This biological complexity is part of what makes it valuable, but it also reflects years of research investment into understanding how these pathways interact, which gets priced into the drug.
The Cost of Proving It Works
Bringing any drug to market costs hundreds of millions of dollars, but cancer drugs face particularly steep hurdles. Cabometyx’s pivotal trial, called METEOR, enrolled 658 patients with advanced kidney cancer across roughly 200 clinical sites in 26 countries. Running a global trial at that scale, with years of follow-up to measure survival outcomes, is enormously expensive. And METEOR was just one of several trials. Exelixis, the company behind Cabometyx, has tested it across multiple cancer types including thyroid cancer and liver cancer, each requiring its own large trial to win FDA approval.
The failure rate in cancer drug development is also a hidden cost built into pricing. Pharmaceutical companies invest in many compounds that never reach the market, and the ones that succeed need to recoup losses from the ones that didn’t.
A Small Patient Population
Cabometyx treats advanced kidney cancer, liver cancer, and certain thyroid cancers. These are serious conditions, but the total number of patients who need this specific drug in any given year is relatively small. The 2019 Medicare data illustrates this clearly: only about 4,300 Medicare beneficiaries filled prescriptions for Cabometyx that year. When a drug serves a limited population, the manufacturer spreads its development and manufacturing costs across fewer patients, which pushes per-patient pricing higher.
Patent Protection Blocks Generic Competition
Cabometyx is protected by more than 15 U.S. patents. The core composition patent, which covers the drug molecule itself, was originally set to expire in September 2024 but received an extension through August 2026. In early 2023, a Delaware federal court upheld that patent against a generic challenger, ruling that no generic version can receive final FDA approval before August 14, 2026.
Until that date, Exelixis faces no generic competition in the U.S., which means there is no downward pricing pressure from cheaper alternatives. Even after 2026, additional patents extending to 2030 could complicate generic entry depending on future legal challenges. This exclusivity window is a major reason the price stays high: the company can set whatever the market will bear without a lower-cost competitor forcing prices down.
How the Pricing System Keeps Costs High
Cancer drug pricing in the U.S. doesn’t work the way most people assume. The list price (called the wholesale acquisition cost, or WAC) is essentially a starting point for negotiations between the manufacturer, insurance companies, and pharmacy benefit managers. Rebates and discounts flow between these parties, but they rarely translate into lower costs for patients. The system incentivizes high list prices because rebates are often calculated as a percentage of that price, meaning everyone in the supply chain benefits from keeping the sticker price elevated.
Other targeted cancer drugs for kidney cancer carry similarly high price tags. This creates a market where no single manufacturer has strong incentive to undercut competitors, since insurers and oncologists choose treatments based primarily on clinical outcomes rather than price differences of a few thousand dollars per month.
What Patients Actually Pay
The roughly $100,000 annual list price is not what most patients pay out of pocket, though the burden varies widely depending on insurance. Exelixis runs a copay assistance program through its patient support services that reduces commercially insured patients’ costs to $0 per month, up to a maximum benefit of $25,000 per year. That cap matters: if your insurer’s share of the cost is structured so that your copay obligations exceed $25,000 annually, you would be responsible for the difference.
Medicare patients cannot use manufacturer copay cards due to federal rules, which leaves them exposed to the coinsurance percentage their plan requires. For a drug costing this much, even a 20% coinsurance obligation means thousands of dollars per month. Some patients qualify for independent charitable foundations that help cover these costs, but availability fluctuates and waiting lists are common.
Uninsured patients may qualify for Exelixis’s separate patient assistance program, which can provide the drug at no cost to those who meet income requirements. The application process typically involves documentation of income and a prescription from an oncologist.
When Prices Might Drop
The most significant potential price reduction hinges on generic entry after the core patent expires in August 2026. Generic versions of oral cancer drugs typically cost 30% to 80% less than the brand-name version, though how quickly generics reach the market depends on how many manufacturers file applications and whether additional patent disputes arise. The patent landscape for Cabometyx includes protections extending to 2030, so the path to full generic competition could take longer than patients hope.
Medicare’s new authority to negotiate prices on certain high-cost drugs could also affect Cabometyx’s pricing in the coming years, depending on whether it is selected for negotiation in future rounds. For now, the combination of patent exclusivity, a small patient population, complex biology, and U.S. pricing norms keeps Cabometyx among the most expensive oral cancer treatments available.